Teknova Q1 Revenue Rises 13% to $11.1M, Clinical Solutions Up 85%
Teknova delivered 13% revenue growth to $11.1M in Q1 2026, with Lab Essentials revenue up 3% to $8.4M and Clinical Solutions soaring 85% to $2.1M. The company reaffirmed full-year 2026 revenue guidance of $42-44M and forecasts free cash outflow below $10M, supported by $17.8M in cash.
1. Q1 2026 Financial Results
Teknova reported total Q1 2026 revenue of $11.1 million, a 13% increase from $9.8 million in Q1 2025. Lab Essentials revenue rose 3% to $8.4 million while Clinical Solutions jumped 85% to $2.1 million, with $537,000 from other products.
2. Profitability & Cash Flow
Gross profit reached $3.8 million with a 34.2% margin, up from 30.7% a year earlier. Operating expenses totaled $8.1 million, resulting in a net loss of $4.6 million (negative $0.08 per share), adjusted EBITDA of negative $2.0 million, and free cash outflow of $3.6 million.
3. 2026 Outlook & Liquidity
The company reaffirmed full-year revenue guidance of $42–44 million and expects free cash outflow below $10 million. At quarter end, cash and short-term investments totaled $17.8 million against $13.2 million of borrowings.